Review shows the involvement of extracellular vesicle miRNAs in sarcopenia, indicating their potential as biomarkers and therapies.
Sarcopenia, defined as progressive loss of skeletal muscle mass and function, occurs during aging and has also been recognized for its detrimental effects in various disease states. Its prevention and management represent a critical aspect of geriatric care and multi‐morbidity management. As a systemic disorder, extracellular vesicle‐transported miRNAs mediate both intrinsic muscle pathology and multifaceted organ crosstalk. This review comprehensively summarizes and discusses the roles of EVs‐miRNAs in sarcopenia under physiological aging and pathological conditions, and their emerging potential as diagnostic biomarkers and engineered therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: